Furthermore, the viability, proliferation, and migration of MM cells has been reported to decrease following treatment with BM-MSC-MVs from healthy donors via the activation of a mitogen-activated protein kinases (MAPK) pathway in contrast to MVs from MM patients [61]. The gene discussed is WNK2; the disease is Miyoshi myopathy.